Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. METHODS: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. RESULTS: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. CONCLUSIONS: Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical benefi t with maintenance ICT in specifi c settings was demonstrated in patients with nonsmall cell lung cancer (NSCLC; ref.50 ), extensive-stage small cell lung cancer ( 51,52 ), and bladder cancer ( 53 ), leading to FDA approvals in these tumor types.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [50]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
Research works printed but not linked: 1
- Ettinger S, Wood DE, Aisner DL, et al. Non-small cell lung cancer, Version 5.2017. J Natl Compr Canc Netw 2017; 15: 504-35.
Cited by
Items 701–800 of 1,008
Nishio, M., Saito, H., Goto, K., Watanabe, S., Sueoka‐Aragane, N., Okuma, Y., Kasahara, K., Chikamori, K., Nakagawa, Y., & Kawakami, T. (2021) · Cancer Science · doi:10.1111/cas.14817 · Cited by 55
Ruysscher, D. D., Ramalingam, S. S., Urbanic, J. J., Gerber, D. E., Tan, D. S. W., Cai, J., Li, A., & Peters, S. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.07.005 · Cited by 56
Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives
Césaire, M., Montanari, J., Curcio, H., Lerouge, D., Gervais, R., Demontrond, P., Balosso, J., & Chevalier, F. (2022) · Cancers · doi:10.3390/cancers14122829 · Cited by 53
Focused ultrasound-assisted delivery of immunomodulating agents in brain cancer
Memari, E., Khan, D. S., Alkins, R. D., & Helfield, B. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.034 · Cited by 51
Sharma, A., Alexander, G., Chu, J. H., Markopoulos, A., Maloul, G., Ayub, M. T., Fidler, M. J., & Okwuosa, T. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032620 · Cited by 52
Kjeldsen, J. W., Iversen, T. Z., Engell-Noerregaard, L., Mellemgaard, A., Andersen, M. H., & Svane, I. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02145 · Cited by 49
Combining stereotactic body radiation therapy with immunotherapy: current data and future directions
Lin, A. J., Roach, M. C., Bradley, J. D., & Robinson, C. G. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.16 · Cited by 49
Ren, S., Tian, Q., Amar, N., Yu, H., Rivard, C. J., Caldwell, C., Ng, T. L., Tu, M. M., Liu, Y., Gao, D., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.004 · Cited by 54
Lesueur, P., Escande, A., Thariat, J., Vauléon, E., Monnet, I., Cortot, A. B., Lerouge, D., Danhier, S., Dô, P., Dubos‐Arvis, C., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1825 · Cited by 50
Remón, J., Hendriks, L. E. L., Cabrera, C., Reguart, N., & Besse, B. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.006 · Cited by 52
Current landscape of palliative radiotherapy for non-small-cell lung cancer
Jumeau, R., Vilotte, F., Durham, A., & Ozsahin, E. M. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.10 · Cited by 52
Dünker, N., & Jendrossek, V. (2019) · Cancers · doi:10.3390/cancers11101499 · Cited by 62
Koomen, B. M., Badrising, S. K., van den Heuvel, M. M., & Willems, S. M. (2019) · Histopathology · doi:10.1111/his.14040 · Cited by 54
Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition
Yuan, J. D., Khilnani, A. D., Brody, J., Andtbacka, R. H. I., Hu‐Lieskovan, S., Luke, J. J., Diab, A. K., Marabelle, A., Snyder, A., Cao, Z. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.004 · Cited by 50
Oh, C. R., Kim, J. E., Hong, Y. S., Kim, S. Y., Ahn, J. B., Baek, J. Y., Lee, M. A., Kang, M. J., Cho, S., Beom, S., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33966 · Cited by 51
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
Banna, G. L., Passiglia, F., Colonese, F., Canova, S., Menis, J., Addeo, A., Russo, A. D., & Cortinovis, D. L. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.016 · Cited by 50
Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy
Tian, Y., Ma, J., Jing, X., Zhai, X., Li, Y., Guo, Z., Yu, J., & Zhu, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215719 · Cited by 51
Qu, T., Zhong, T., Pang, X., Huang, Z., Jin, C., Wang, Z. M., Li, B., & Xia, Y. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005517 · Cited by 53
Grassi, E., Zingaretti, C., Petracci, E., Corbelli, J., Papiani, G., Banchelli, I., Valli, I., Frassineti, G. L., Passardi, A., Bartolomeo, M. D., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101824 · Cited by 53
Liu, W., Puri, A., Fu, D., Chen, L., Wang, C., Kellis, M., & Yang, J. (2023) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10246-2 · Cited by 54
Roach, M. C., Bradley, J. D., & Robinson, C. G. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.153 · Cited by 48
Current Landscape of Immunotherapy for the Treatment of Metastatic Non-Small-Cell Lung Cancer
Pabani, A., & Butts, C. A. (2018) · Current Oncology · doi:10.3747/co.25.3750 · Cited by 51
Cost-of-Illness Study for Non-Small-Cell Lung Cancer Using Real-World Data
Seung, S. J., Hurry, M. V., Hassan, S., Walton, R. N., & Evans, W. K. (2019) · Current Oncology · doi:10.3747/co.26.4555 · Cited by 50
Sakaguchi, T., Ito, K., Furuhashi, K., Nakamura, Y., Suzuki, Y., Nishii, Y., Taguchi, O., & Hataji, O. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.03.011 · Cited by 49
Mechanisms of immunogenicity in colorectal cancer
Sillo, T. O., Beggs, A. D., Morton, D. G., & Middleton, G. (2019) · British journal of surgery · doi:10.1002/bjs.11204 · Cited by 53
Immune checkpoint: The novel target for antitumor therapy
Jiang, X., Liu, G., Li, Y., & Pan, Y. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.12.004 · Cited by 54
Thomas, R., Chen, Y., Hatabu, H., Mak, R. H., & Nishino, M. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.023 · Cited by 49
Workenhe, S. T., Nguyen, A., Bakhshinyan, D., Wei, J., Hare, D. N., MacNeill, K. L., Wan, Y., Oberst, A., Bramson, J. L., Nasir, J. A., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01362-w · Cited by 56
The role of radiotherapy in the age of immunotherapy
Sato, H., Demaria, S., & Ohno, T. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa268 · Cited by 52
Tan, Z.-L., Yue, C., Ji, S., Zhao, C., Jia, R., Zhang, Y., Liu, R., Li, D., Yu, Q., Li, P., et al. (2021) · The Oncologist · doi:10.1002/onco.13981 · Cited by 50
Managing Central Nervous System Spread of Lung Cancer: The State of the Art
Tsui, D. C. C., Camidge, D. R., & Rusthoven, C. G. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01715 · Cited by 50
Immunotherapy for Unresectable Stage III Non–Small-Cell Lung Cancer
Rizvi, N. A., & Peters, S. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711430 · Cited by 48
Lindqvist, J., Jekunen, A. P., Sihvo, E. I. T., Johansson, M., & Andersén, H. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.07.006 · Cited by 52
Advances in immunotherapy for cervical cancer
Grau-Béjar, J. F., García-Durán, C., García-Illescas, D., Mirallas, O., & Oaknin, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231163836 · Cited by 56
Wu, L., Zhang, Z., Bai, M., Yan, Y., Yu, J., & Xu, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01139-8 · Cited by 53
Dervovic, D., Malik, A., Chen, E. L. Y., Narimatsu, M., Adler, N., Afiuni‐Zadeh, S., Krenbek, D., Martinez, S., Tsai, R., Boucher, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38841-7 · Cited by 56
Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives
Kapoor, D. U., Gandhi, S. M., Swarn, S., Lal, B., Prajapati, B. G., Khondee, S., Mangmool, S., Singh, S. K., & Chittasupho, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091091 · Cited by 54
Combination Immunotherapy Development in Melanoma
Eggermont, A. M. M., Crittenden, M. R., & Wargo, J. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201131 · Cited by 54
Fumet, J.-D., Isambert, N., Hervieu, A., Zanetta, S., Guion, J.-F., Hennequin, A., Rederstorff, E., Bertaut, A., & Ghiringhelli, F. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000375 · Cited by 48
Radiation Recall Pneumonitis in the Setting of Immunotherapy and Radiation: a Focused Review
McGovern, K., Ghaly, M. M., Esposito, M., Barnaby, K., & Seetharamu, N. (2019) · Future Science OA · doi:10.2144/fsoa-2018-0123 · Cited by 49
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 51
Radiation and immunotherapy: emerging mechanisms of synergy
Breen, W. G., Leventakos, K., Dong, H., & Merrell, K. W. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-2019-cptn-07 · Cited by 49
Stares, M., Swan, A. M., Cumming, K., Ding, T.-E., Leach, J., Stratton, C., Thomson, F., Barrie, C., Maclennan, K., Campbell, S., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.734735 · Cited by 48
The use of immunotherapy in older patients with advanced non-small cell lung cancer
Tagliamento, M., Frélaut, M., Baldini, C., Naigeon, M., Nencioni, A., Chaput, N., & Besse, B. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102394 · Cited by 53
Orlando, E., Aebersold, D. M., Medová, M., & Zimmer, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.12.001 · Cited by 47
CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Ghazi, B., El Ghanmi, A., Kandoussi, S., Ghouzlani, A., & Badou, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978195 · Cited by 46
Voronova, V., Vislobokova, A., Mutig, K., Samsonov, M., Peskov, K. V., Sekacheva, M. I., Materenchuk, M. Y., Bunyatyan, N. D., & Lebedeva, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1035884 · Cited by 50
Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies
Jia, H., Jiang, L., Shen, X., Ye, H., Li, X., Zhang, L., Hu, Y., Song, D., Jia, H., & Wang, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02397-5 · Cited by 60
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
Toschi, L., Rossi, S., Finocchiaro, G., & Santoro, A. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.787 · Cited by 53
Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence?
Jones, C. M., Brunelli, A., Callister, M. E. J., & Franks, K. (2018) · Current Surgery Reports · doi:10.1007/s40137-018-0202-0 · Cited by 46
Metformin for non-small cell lung cancer patients: Opportunities and pitfalls
Lévy, A., & Doyen, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.001 · Cited by 49
Cavalieri, S., Rivoltini, L., Bergamini, C., Locati, L. D., Licitra, L. F., & Bossi, P. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.03.003 · Cited by 49
Park, S. E., Noh, J. M., Kim, Y. J., Lee, H. S., Cho, J. H., Lim, S. W., Ahn, Y. C., Pyo, H., Choi, Y., Han, J., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.125 · Cited by 47
Self-citationPatel, R. B., Baniel, C., Sriramaneni, R. N., Bradley, K. A., Markovina, S. T., & Morris, Z. S. (2018) · Brachytherapy · doi:10.1016/j.brachy.2018.07.004 · Cited by 49
Trefny, M. P., Rothschild, S. I., Uhlenbrock, F., Rieder, D., Kasenda, B., Stanczak, M. A., Berner, F., Kashyap, A. S., Kaiser, M., Herzig, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3041 · Cited by 51
Li, F., Li, Z., Jin, X., Liu, Y., Zhang, P., Li, P., Shen, Z., Wu, A., Chen, W., & Li, Q. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s193676 · Cited by 46
Combining Immunotherapy and Chemotherapy for Non–Small Cell Lung Cancer
Judd, J., & Borghaei, H. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.006 · Cited by 51
Suzuki, K., Yanagihara, T., Matsumoto, K., Kusaba, H., Yamauchi, T., Ikematsu, Y., Tanaka, K., Otsubo, K., Inoue, H., Yoneshima, Y., et al. (2020) · International Immunology · doi:10.1093/intimm/dxaa022 · Cited by 49
Fasano, M., Corte, C. M. D., Liello, R. D., Barra, G., Sparano, F., Viscardi, G., Iacovino, M. L., Paragliola, F., Famiglietti, V., Ciaramella, V., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000753 · Cited by 50
Dempke, W. C. M., Fenchel, K., & Dale, S. P. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.04.18 · Cited by 46
Sung, W., Hong, T. S., Poznansky, M. C., Paganetti, H., & Grassberger, C. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.11.008 · Cited by 47
Chen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 50
Araujo, L. H., Horn, L., Merritt, R. E., Shilo, K., Xu‐Welliver, M., & Carbone, D. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00069-4 · Cited by 48
Current status of immunotherapy for non-small cell lung cancer
Yang, T., Xiong, Y., Zeng, Y., Wang, Y., Zeng, J., Liu, J., Xu, S., & Li, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989461 · Cited by 49
Chen, N., Xiong, M., Zhou, R., Zhou, Y., Qiu, B., Luo, Y., Su, Z., Chu, C., Li, Q., Wang, B., et al. (2022) · Radiation Oncology · doi:10.1186/s13014-022-02136-w · Cited by 44
Self-citationAdjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone
Tang, W., Ye, H.-Y., Tang, X., Su, J., Xu, K.-M., Zhong, W., & Liang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1063183 · Cited by 46
Shi, F., Huang, X., Hong, Z., Lü, N., Huang, X., Liu, L., Liang, T., & Bai, X. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216167 · Cited by 50
Morris, Z. S., Demaria, S., Monjazeb, A. M., Formenti, S. C., Weichselbaum, R. R., Welsh, J. D., Enderling, H., Schoenfeld, J. D., Brody, J., McGee, H. M., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00656-9 · Cited by 50
Nanotechnology for immuno-oncology
Grippin, A., Lee, D., Parkes, E. E., Jiang, W., & Kim, B. Y. S. (2025) · Nature Cancer · doi:10.1038/s43018-025-01025-x · Cited by 57
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
Yang, H. J., Shen, K., Zhu, C., Li, Q., Zhao, Y., & Ma, X. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s162214 · Cited by 46
Sasaki, T., Seto, T., Yamanaka, T., Kunitake, N., Shimizu, J., Kodaira, T., Nishio, M., Kozuka, T., Takahashi, T., Harada, H., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0243-2 · Cited by 45
Spaas, M., & Lievens, Y. N. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00244 · Cited by 45
Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy
Kabiljo, J., Harpain, F., Carotta, S., & Bergmann, M. M. (2019) · Cancers · doi:10.3390/cancers12010079 · Cited by 49
Ye, X., Wei, Z., Yang, X., Huang, G., Li, W., Han, X., Wang, J., Meng, M., Ni, Y., Zou, Z., et al. (2019) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_990_19 · Cited by 45
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
Zhu, C., Zhuang, W., Chen, L., Yang, W., & Ou, W. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.09 · Cited by 50
Yan, X., Tian, X., Wu, Z., & Han, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01671 · Cited by 48
Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
Tfayli, A., Assaad, M. A., Fakhri, G. B., Akel, R., Atwi, H., Ghanem, H., Karak, F. E., Farhat, F. S., rabi, K. A., Sfeir, P. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3456 · Cited by 45
Taugner, J., Käsmann, L., Eze, C., Rühle, A., Tufman, A., Reinmuth, N., Duell, T., Belka, C., & Manapov, F. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01091-9 · Cited by 50
Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
Xiong, W. G., Zhao, Y., Du, H., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704336 · Cited by 51
(2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0422-y · Cited by 44
PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
Zhang, Y., Yang, Y., Chen, Y., Wu, L., Chen, X., Liu, J., Huang, Y., Wang, H., & Teng, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1060497 · Cited by 45
Self-citationRe-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy
Chen, F., Niu, J., Wang, M., Zhu, H., & Guo, Z. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04212-5 · Cited by 52
Friedes, C., Iocolano, M., Lee, S. H., Duan, L., Li, B., Doucette, A. G., Cohen, R. B., Aggarwal, C., Sun, L., Levin, W. P., et al. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.110030 · Cited by 56
Laryngeal Cancer in the Modern Era: Evolving Trends in Diagnosis, Treatment, and Survival Outcomes
Hut, A.-R., Boia, E. R., Para, D. M., Iovănescu, G., Horhat, D. I., Mikša, L., Chiriac, M., Galant, R., Motofelea, A. C., & Balica, N. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103367 · Cited by 56
Management of stage III non–small cell lung cancer
Tabchi, S., Kassouf, E., Rassy, E., Kourié, H. R., Martin, J., Campeau, M., Tehfe, M. A., & Blais, N. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.10.009 · Cited by 44
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
Clarke, J. M., George, D. J., Lisi, S., & Salama, A. K. S. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0549-7 · Cited by 46
Remón, J., Vilariño, N., & Reguart, N. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.002 · Cited by 50
Cheng, M., Jolly, S., Quarshie, W. O., Kapadia, N. S., Vigneau, F. D., & Kong, F. (2018) · Journal of Cancer · doi:10.7150/jca.26600 · Cited by 52
Wang, C., Park, J., Ouyang, C., Longmate, J., Tajon, M., Chao, J., Lim, D. W., Sandhu, J. S., Yin, H. H., Pillai, R. K., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0924 · Cited by 47
Hansen, R. N., Zhang, Y., Seal, B. S., Ryan, K. J., Yong, C., Darilay, A. T., & Ramsey, S. D. (2020) · BMC Cancer · doi:10.1186/s12885-020-06734-3 · Cited by 52
Eichkorn, T., Bozorgmehr, F., Regnery, S., Dinges, L. A., Kudak, A., Bougatf, N., Weber, D., Christopoulos, P., Muley, T., Kobinger, S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586449 · Cited by 45
Huang, Q., Zheng, Y., Gao, Z., Yuan, L., Sun, Y., & Chen, H. (2020) · Journal of Cancer · doi:10.7150/jca.49325 · Cited by 48
Zhang, F., Ferrero, M., Dong, N., D’Auria, G., Reyes-Prieto, M., Herreros-Pomares, A., Calabuig-Fariñas, S., Duréndez, E., Aparisi, F., Blasco, A., et al. (2021) · Cancers · doi:10.3390/cancers13112514 · Cited by 43
Molecular testing in stage I–III non-small cell lung cancer: Approaches and challenges
Aggarwal, C., Bubendorf, L., Cooper, W. A., Illei, P. B., Borralho, P., Ong, B., Tsao, M., Yatabe, Y., & Kerr, K. M. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.09.003 · Cited by 50
Sankar, K. N., Bryant, A. K., Strohbehn, G. W., Zhao, L., Elliott, D., Moghanaki, D. M., Kelley, M. J., Ramnath, N., & Green, M. D. (2022) · Cancers · doi:10.3390/cancers14030614 · Cited by 46
de Goeje, P. L., Poncin, M., Bezemer, K., Kaijen-Lambers, M. E. H., Groen, H. J. M., Smit, E. F., Dingemans, A.-M. C., Kunert, A., Hendriks, R. W., & Aerts, J. G. J. V. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2243 · Cited by 43
Radiopharmaceuticals heat anti-tumor immunity
Sun, Q., Li, J., Ding, Z., & Liu, Z. (2023) · Theranostics · doi:10.7150/thno.79806 · Cited by 45
Liu, C., Wei, W., Yang, L., Li, J., Cheng, Y., Pu, Y., Yin, T., Na, F., Zhang, L., Fu, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1173952 · Cited by 46
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
Attili, I., Passaro, A., Corvaja, C., Aliaga, P. T., Signore, E. D., Spitaleri, G., & de Marinis, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102602 · Cited by 47
RETRACTED: Advancing cancer theranostics through biomimetics: A comprehensive review
Anitha, K., Chenchula, S., Surendran, V., Bhatt, S., Ravula, P., Milan, R., Chikatipalli, R., & Padmavathi, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27692 · Cited by 44
Retracted
Metadata
- Authors
- Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeño, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A., & Özgüroğlu, M.
- Affiliations
- Institut Gustave Roussy (FR)
- From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) — all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville — both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and...
- ORCID
- Antonia, Scott J.
- Villegas, Augusto
- Daniel, Davey
- Vicente, David
- Murakami, Shuji
- Hui, Rina
- Yokoi, Takashi
- Chiappori, Alberto
- Lee, Ki H.
- Cho, Byoung C.
- Quantin, Xavier
- Tokito, Takaaki
- Planchard, David
- Kim, Young-Chul
- Karapetis, Christos S.
- Hiret, Sandrine
- Ostoros, Gyula
- Kubota, Kaoru
- Gray, Jhanelle E.
- Paz-Ares, Luis
- Jiang, Haiyi
- Huang, Yifan
- Özgüroğlu, Mustafa
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-16
- Volume
- 377
- Issue
- 20
- Pages
- 1919-1929
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2753065806
- Cited by
- 4,593
- References
- 22
- Citations by year
- 2026: 380 · 2025: 463 · 2024: 496 · 2023: 548 · 2022: 555 · 2021: 625 · 2020: 563 · 2019: 463 · 2018: 451 · 2017: 46
- FWCI
- 183.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- HAL (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Cancer Research UK (20465)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- durvalumab, non-small cell lung cancer, stage III NSCLC, consolidation therapy, chemoradiotherapy, PD-L1 inhibitors, progression-free survival, overall survival, objective response rate, locally advanced unresectable lung cancer, immune checkpoint inhibitors, platinum-based chemotherapy, radiotherapy, distant metastasis, treatment safety, adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, Chemoradiotherapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.